Neurophysiological Markers in the Depressive Episode Characterized by Anhedonic Drug Resistance: Evaluation of Motor Skills and P300 Wave
Overview
- Phase
- Not Applicable
- Intervention
- Electroencephalogram
- Conditions
- Bipolar Anhedonic Depression
- Sponsor
- University Hospital, Rouen
- Enrollment
- 36
- Locations
- 2
- Primary Endpoint
- Difference between latency of P300 wave during encephalogram
- Status
- Terminated
- Last Updated
- 2 months ago
Overview
Brief Summary
Depression is currently the leading cause of disability and suicide death worldwide. Several studies, however, have shown that a significant proportion of patients do not respond to standard antidepressants, especially since their symptomatology is dominated by anhedonia or psychomotor retardation reflecting central dopaminergic dysfunction. In order to improve the efficiency and speed of the antidepressant response, it seems essential to highlight this dopaminergic dysfunction, by defining a P300 wave profile specific to the subtype of depressed patients with anhedonic phenotype to whom personalized treatment targeting dopaminergic transmission could in the future be proposed earlier. The investigators therefore wish to highlight an increase in the latency time of P300 and a modification of motor skills (of the walking cycle and of the movement of the hands), without modification of the dopaminergic transmission measured by PETScan, specific to the sub-type of depressive patients, resistant to at least 2 antidepressants of different classes with an anhedonia score> 5/14 on the SHAPS scale. The increased latency of P300 could then be used in the future as a predictive biomarker of resistance to conventional antidepressant treatments specific to this population of anhedonic depressed patients
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy volunteers:
- •Person who is ≥ 18 years old and ≤ 70 years old
- •Subject without neurological history
- •Subject without psychiatric history in the semi-structured interview Mini International Neuropsychiatric Interview (MINI).
- •Subject having read and understood the newsletter and signed the consent form
- •Subject affiliated to a social security scheme.
- •Subject capable of understanding spoken and written French.
- •Woman of reproductive age with effective contraception as defined by the WHO, for at least three months or postmenopausal.
- •Patients with drug-resistant bipolar anhedonic depression:
- •Patient whose age is ≥ 18 years and ≤ 70 years.
Exclusion Criteria
- •Healthy volunteers:
- •Person with a psychiatric disorder in the semi-structured interview Mini International Neuropsychiatric Interview (MINI) (Annex 9).
- •Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship.
- •Subjects with poor understanding of spoken or written French
- •Existence of a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters.
- •Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding.
- •Taking unauthorized treatment during the study and:
- •In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT).
- •In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics.
- •In the 2 months preceding inclusion for electroconvulsive therapy
Arms & Interventions
Healthy volunteers
Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
Intervention: Electroencephalogram
Healthy volunteers
Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
Intervention: walking test
Healthy volunteers
Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
Intervention: Quality of life questionnaire
Anhedonic drug-resistant bipolar depression patient
Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
Intervention: Electroencephalogram
Anhedonic drug-resistant bipolar depression patient
Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
Intervention: walking test
Anhedonic drug-resistant bipolar depression patient
Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
Intervention: Quality of life questionnaire
Anhedonic drug-resistant bipolar depression patient
Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
Intervention: Position emission tomography
Non-anhedonic drug-resistant bipolar depression Pat
Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
Intervention: Electroencephalogram
Non-anhedonic drug-resistant bipolar depression Pat
Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
Intervention: walking test
Non-anhedonic drug-resistant bipolar depression Pat
Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
Intervention: Quality of life questionnaire
Non-anhedonic drug-resistant bipolar depression Pat
Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
Intervention: Position emission tomography
Mild to moderate Parkinson's disease patient
Adult patients at least 18 years of age with mild to moderate Parkinson's disease
Intervention: Electroencephalogram
Mild to moderate Parkinson's disease patient
Adult patients at least 18 years of age with mild to moderate Parkinson's disease
Intervention: walking test
Mild to moderate Parkinson's disease patient
Adult patients at least 18 years of age with mild to moderate Parkinson's disease
Intervention: Quality of life questionnaire
Mild to moderate Parkinson's disease patient
Adult patients at least 18 years of age with mild to moderate Parkinson's disease
Intervention: Position emission tomography
Outcomes
Primary Outcomes
Difference between latency of P300 wave during encephalogram
Time Frame: 1 hour after inclusion
Secondary Outcomes
- Difference in walking speed during an 8 meter-walk test between the group of patients with bipolar drug-resistant depression of the anhedonic type and the other groups of subjects(2 hours after inclusion)
- Stride length variation during an 8 meter-walk test between the group of patients with bipolar drug-resistant depression of the anhedonic type and the other groups of subjects(2 hours after inclusion)
- Difference in presynaptic fixation of 18-Fluorodopa during positron emission tomography between the group of patients with drug-resistant bipolar depression of the anhedonic type and the other groups of patients(4 hours after inclusion)
- Difference in the apathy assessment score performed by the Starkstein Apathy Scale (SAS) between the group of patients with drug-resistant bipolar depression of the anhedonic type and the other groups of subjects(30 minutes after inclusion)
- Difference in frequency of melancholic characteristics meeting the criteria of DSM-5 between the group of patients with drug-resistant bipolar depression of the anhedonic type and the other groups of subjects(30 minutes after inclusion)
- Difference in the Montgomery-Åsberg Depression Rating Scale (MADRS) assessment score for EDC severity between the group of patients with bipolar drug-resistant depression of the anhedonic type and the other groups of subjects(30 minutes after inclusion)
- Difference in the score for evaluation of repetitive negative thinking by the Perseverative Thinking Questionnaire (PTQ) between the group of patients with bipolar drug-resistant(30 minutes after inclusion)
- Difference in the score for the evaluation of parkinsonian symptoms (classification of Hoehn & Yahr) between the group of patients with bipolar drug-resistant depression of the anhedonic type and the other groups of patients(30 minutes after inclusion)